| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
H-Tyr-Phe-OH targets multiple enzymes and pathways. It inhibits angiotensin-converting enzyme (ACE) with an inhibition rate of 48% at 50 μM, suggesting potential antihypertensive activity. It also exhibits xanthine oxidase inhibitory (uric acid-lowering) activity. Additionally, it regulates IL-8 production in neutrophil-like cells. These diverse activities make it a compound of interest for studying cardiovascular, metabolic, and inflammatory processes.
|
|---|---|
| ln Vitro |
In vitro, H-Tyr-Phe-OH demonstrates ACE inhibitory activity with an inhibition rate of 48% at 50 μM. It also shows xanthine oxidase inhibitory activity and regulates IL-8 production in neutrophil-like cells. These activities suggest potential applications in hypertension, gout, and inflammation research. The compound's ability to inhibit ACE and xanthine oxidase makes it a valuable tool for studying these enzymes.
|
| ln Vivo |
In vivo, H-Tyr-Phe-OH is orally active, suggesting it may have potential as an orally bioavailable therapeutic agent. Its ACE inhibitory activity could translate to antihypertensive effects in vivo. However, specific in vivo efficacy data are not extensively documented. The compound is used as a biomarker for thyroid cancer research.
|
| Enzyme Assay |
In vitro enzyme assays are used to characterize H-Tyr-Phe-OH's activity. ACE inhibition assays measure the compound's ability to inhibit ACE-mediated cleavage of a substrate. Xanthine oxidase inhibition assays measure the compound's ability to inhibit the conversion of xanthine to uric acid. IL-8 production can be measured in neutrophil-like cells treated with the compound.
|
| Cell Assay |
Cell-based assays for H-Tyr-Phe-OH are conducted in neutrophil-like cells to assess its effects on IL-8 production. Cells are treated with the compound at various concentrations, and IL-8 levels in the supernatant are measured by ELISA. Cytotoxicity is assessed in parallel. These assays characterize the compound's immunomodulatory effects.
|
| Animal Protocol |
In vivo animal experiments with H-Tyr-Phe-OH are not extensively documented. As an orally active ACE inhibitor, it could be tested in hypertensive animal models to assess its blood pressure-lowering effects. It could also be evaluated in models of gout to assess its uric acid-lowering effects. Specific protocols are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of H-Tyr-Phe-OH include oral activity, indicating reasonable oral bioavailability. The compound has a molecular formula of C18H20N2O4 and a molecular weight of 328.36. It is a solid. Storage: powder at -20°C for 3 years; in solvent at -80°C for 6 months. Specific PK parameters are not available.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for H-Tyr-Phe-OH are limited. As a dipeptide, it is expected to have low toxicity. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed. No specific toxicity data are available.
|
| References |
|
| Additional Infomation |
Tyr-Phe is a dipeptide formed from L-tyrosine and L-phenylalanine residues; it is a metabolite.
H-Tyr-Phe-OH has CAS number 17355-11-2, molecular formula C18H20N2O4, and molecular weight 328.36. It is a dipeptide composed of tyrosine and phenylalanine. It is an orally active ACE inhibitor (48% inhibition at 50 μM), has xanthine oxidase inhibitory activity, and regulates IL-8 production. It can be used as a thyroid cancer biomarker. Not for human use; for research purposes only. |
| Molecular Formula |
C18H20N2O4
|
|---|---|
| Molecular Weight |
328.3624
|
| Exact Mass |
328.142
|
| CAS # |
17355-11-2
|
| PubChem CID |
7009600
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3 g/cm3
|
| Boiling Point |
642.2ºC at 760 mmHg
|
| Flash Point |
342.2ºC
|
| Vapour Pressure |
2.27E-17mmHg at 25°C
|
| Index of Refraction |
1.625
|
| LogP |
2.165
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
24
|
| Complexity |
415
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N
|
| InChi Key |
CGWAPUBOXJWXMS-HOTGVXAUSA-N
|
| InChi Code |
InChI=1S/C18H20N2O4/c19-15(10-13-6-8-14(21)9-7-13)17(22)20-16(18(23)24)11-12-4-2-1-3-5-12/h1-9,15-16,21H,10-11,19H2,(H,20,22)(H,23,24)/t15-,16-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~15.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0454 mL | 15.2272 mL | 30.4544 mL | |
| 5 mM | 0.6091 mL | 3.0454 mL | 6.0909 mL | |
| 10 mM | 0.3045 mL | 1.5227 mL | 3.0454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
